ERBB2 and prostate cancer: It has reported that AKT inhibitor GSK690693 promotes the transcriptional induction of Pim1 kinase, which increased the protein expressions of receptor tyrosine kinase (RTK), including EGFR, HER2, and HER3, and subsequently resulted in the resistance of prostate cancer cells to AKT inhibition (Cen et al., 2013).